Drug
MK0457
MK0457 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 20.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
20.0%
Based on 1 completed trials
Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
4(80%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
20.0%
1 of 5 finished
Non-Completion Rate
80.0%
4 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(1)
Terminated(4)
Detailed Status
Terminated4
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
terminated480%
completed120%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_1
A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
NCT02532868
completedphase_1
MK0457 in Patients With Leukemia (0457-003)
NCT00111683
terminatedphase_2
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
NCT00290550
terminatedphase_1
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
NCT00500006
terminatedphase_2
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
NCT00405054
Clinical Trials (5)
Showing 5 of 5 trials
NCT02532868Phase 1
A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
NCT00111683Phase 1
MK0457 in Patients With Leukemia (0457-003)
NCT00290550Phase 2
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
NCT00500006Phase 1
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
NCT00405054Phase 2
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5